Corbus Pharmaceuticals Holdings Inc 2026年季度报告

FORM 10-Q PART I — FINANCIAL INFORMATION Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Balance Sheets(in thousands, except share and per share amounts) March 31, 2026December 31, 2025 Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Statements of Operations and Comprehensive Loss Corbus Pharmaceuticals Holdings, Inc.Condensed Consolidated Statements of Stockholders’ Equity Corbus Pharmaceuticals Holdings, Inc.Notes to Unaudited Condensed Consolidated Financial Statements 1.NATURE OF BUSINESS AND BASIS OF PRESENTATION Nature of Business Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a clinical-stage company focused on developingpromising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringinginnovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate ("ADC") for the treatment of Nectin-4-expressing tumors and CRB-913, an orallydelivered highly peripherally restricted cannabinoid type-1 ("CB1") inverse agonist for the treatment of obesity. Since itsinception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with generally accepted accountingprinciples in the United States ("U.S. GAAP") for interim financial reporting. In the opinion of management of the Company,the accompanying unaudited condensed consolidated interim financial statements reflect all adjustments (which include onlynormal recurring adjustments) necessary to present fairly, in all material respects, the condensed consolidated financial positionof the Company as of March 31, 2026 and the results of its operations and changes in stockholders’ equity for the three monthsended March 31, 2026 and 2025 and its cash flows for the three months ended March 31, 2026 and 2025. Certain amounts intheprior year's financial statements have been reclassified to conform with the current year presentation.Thesereclassifications did not impact previously reported net loss or cash flows. The December 31, 2025 condensed consolidated Basis of Consolidation The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. Allsignificant intercompany transactions and accounts have been eliminated in consolidation. The significant accounting policies used in preparation of these condensed consolidated financial statements in this Form 10-Qare consistent with those discussed in Note 3, "Significant Accounting Policies," in our 2025 Annual Report. 2.LIQUIDITY The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as agoing concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities andcommitments in the normal course of business. The Company has incurred recurring losses since inception and as of March 31,2026, had an accumulated deficit of approximately $578.4 million. The Company anticipates operating losses to continue forthe foreseeable future due to, among other things, costs related to research funding, development of its product candidates andits pre-clinical and clinical programs, strategic alliances, and the development of its administrative organization. Based on The source, timing and availability of any future financing will depend principally upon market conditions, and, morespecifically, on the progress of the Company’s clinical development programs. Funding may not be available when needed, atall, or on terms acceptable to the Company. Lack of necessary funds may require the Company to, among other things, delay, The Company filed a new shelf registration statement which was declared effective on March 20, 2026 for which the Companyis authorized to offer and sell securities up to $300 million. 3. CASH, CASH EQUIVALENTS, AND RESTRICTED CASH The Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within 90days from the date of purchase to be cash equivalents. At March 31, 2026 and December 31, 2025, cash equivalents were Restricted cash as of March 31, 2026 included security for a stand-by letter of credit issued in favor of a landlord for $0.4million, all of which was classified in current assets as of March 31, 2026. Cash, cash equivalents, and restricted cash consist of the following (in thousands): As of March 31, 2026, the Company’s cash and cash equivalents held in the U.S. was approximately $24.1 million andapproximately $1.6 million of cash was held in its subsidiaries in the U.K. and Australia. As of December 31, 2025, all of the 4. INVESTMENTS The following table summarizes the Company’s investments as of March 31, 2026 (in thousands): The following t